Abstract

An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.

Author affiliations

1. School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India.
2. School of Environmental Sciences, Jawaharlal Nehru University, New Delhi 110067, India.
3. Channing Laboratory, Department of Medicine, Brigham and Women Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
4. Unité de Génomique des Microorganismes Pathogénes—URA CNRS 2171, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 , Paris Cedex 15, France.
5. Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy.

Correspondence to: Atul Kumar Johri¹ Email: akjohri14@yahoo.com

Published online 6 November 2006

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.